These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29053130)

  • 21. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism.
    Oficialdegui AM; Martinez J; Pérez S; Heras B; Irurzun M; Palop JA; Tordera R; Lasheras B; del Río J; Monge A
    Farmaco; 2000 May; 55(5):345-53. PubMed ID: 10983279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multimodal serotonergic antidepressants].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):103-111. PubMed ID: 29053130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Developments on Future Antidepressant-related Serotonin Receptors.
    Amidfar M; Kim YK
    Curr Pharm Des; 2018; 24(22):2541-2548. PubMed ID: 30073919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs.
    Mandrioli R; Protti M; Mercolini L
    Curr Med Chem; 2018; 25(7):772-792. PubMed ID: 28707591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission.
    Pehrson AL; Jeyarajah T; Sanchez C
    CNS Spectr; 2016 Apr; 21(2):162-83. PubMed ID: 26250622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel serotonergic mechanisms and clinical experience with nefazodone.
    Fontaine R
    Clin Neuropharmacol; 1993; 16 Suppl 3():S45-50. PubMed ID: 8131154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants?
    Puzantian T; Kawase K
    Pharmacotherapy; 1999 Feb; 19(2):205-12. PubMed ID: 10030770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of antidepressants: selectivity or multiplicity?
    Westenberg HG
    J Clin Psychiatry; 1999; 60 Suppl 17():4-8; discussion 46-8. PubMed ID: 10446734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine.
    Pehrson AL; Leiser SC; Gulinello M; Dale E; Li Y; Waller JA; Sanchez C
    Eur J Pharmacol; 2015 Apr; 753():19-31. PubMed ID: 25107284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antidepressants, stressors and the serotonin 1A receptor].
    Kirilly E; Gonda X; Bagdy G
    Neuropsychopharmacol Hung; 2015 Jun; 17(2):81-9. PubMed ID: 26192901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.
    Stahl SM
    J Clin Psychiatry; 1998; 59 Suppl 4():5-14. PubMed ID: 9554316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the Antidepressant Activity of Selective Serotonin Reuptake Inhibitors Mediated by Nicotinic Acetylcholine Receptors?
    Arias HR; Targowska-Duda KM; García-Colunga J; Ortells MO
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonergic drugs for depression and beyond.
    Stahl SM; Lee-Zimmerman C; Cartwright S; Morrissette DA
    Curr Drug Targets; 2013 May; 14(5):578-85. PubMed ID: 23531115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.
    Köhler S; Cierpinsky K; Kronenberg G; Adli M
    J Psychopharmacol; 2016 Jan; 30(1):13-22. PubMed ID: 26464458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function.
    Dale E; Pehrson AL; Jeyarajah T; Li Y; Leiser SC; Smagin G; Olsen CK; Sanchez C
    CNS Spectr; 2016 Apr; 21(2):143-61. PubMed ID: 26346726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters.
    Stahl SM
    CNS Spectr; 2015 Dec; 20(6):515-9. PubMed ID: 26062986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs.
    Lucki I; O'Leary OF
    J Clin Psychiatry; 2004; 65 Suppl 4():11-24. PubMed ID: 15046537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
    Dawson LA; Watson JM
    CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.